Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Polyus reported for 6 months of 2023 by IFRS

8/29/23 PLZL

Kamaz resumes production of trucks with Euro-5 engine

8/29/23 KMAZ

Yuzhuralnickel reported for 6 months of 2023 by IFRS

8/29/23 UNKL

Slavneft-Yaroslavnefteorgsintez reported for 6 months of 2023 by IFRS

8/29/23 JNOS

Permenergosbyt reported for 6 months of 2023 by IFRS

8/29/23 PMSB

Board of Directors of Donskoy Factory of Radiocomponents recommended that dividends be paid for 6 months 2023

8/29/23 DZRD

Shareholders of TMK approved dividends for 6 months 2023

8/29/23 TRMK

Xiaomi reported for 6 months of 2023

8/29/23 1810

TNS Energy Yaroslavl reported for 6 months of 2023 by IFRS

8/29/23 YRSB

DIOD reported for 6 months of 2023 by IFRS

8/29/23 DIOD